Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic

Press Release

Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic NEWS PROVIDED BY Alphyn Biologics Oct 27, 2025, 07:30 ET Patent covers active pharmaceutical ingredient with protection until 2041 ANNAPOLIS, Md., Oct. 27, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office…

15th Georg RAJKA ISAD Presentation: Zabalafin Hydrogel – A Novel Topical Botanical Drug That Addresses the Four Demons of Atopic Dermatitis

Clinical Presentations

15th Georg RAJKA International Symposium on Atopic Dermatitis Presentation: Zabalafin Hydrogel – A Novel Topical Botanical Drug That Addresses the Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics October 27, 2025, 07:30 ET 1168_Neal-KOLLER_phase-2b-trial-of-zabalafin-hydrogel-a-novel-topical-botanical-drug-that-addresses-the-four-demons-of-atopic-dermatitis CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195